Suppr超能文献

相似文献

1
The role of hepatokines in NAFLD.
Cell Metab. 2023 Feb 7;35(2):236-252. doi: 10.1016/j.cmet.2023.01.006.
2
Hepatokines and non-alcoholic fatty liver disease.
Acta Biochim Pol. 2016;63(3):459-67. doi: 10.18388/abp.2016_1252. Epub 2016 Jun 6.
3
Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines.
Expert Rev Gastroenterol Hepatol. 2016;10(3):393-403. doi: 10.1586/17474124.2016.1110485. Epub 2015 Dec 14.
5
Hepatokines and adipokines in NASH-related hepatocellular carcinoma.
J Hepatol. 2021 Feb;74(2):442-457. doi: 10.1016/j.jhep.2020.10.030. Epub 2020 Nov 5.
6
Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance.
Nat Rev Endocrinol. 2017 Sep;13(9):509-520. doi: 10.1038/nrendo.2017.56. Epub 2017 Jun 9.
7
Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
World J Gastroenterol. 2014 Jul 28;20(28):9330-7. doi: 10.3748/wjg.v20.i28.9330.
8
Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism.
Biomedicines. 2021 Dec 14;9(12):1903. doi: 10.3390/biomedicines9121903.

引用本文的文献

1
Interplay between endocrine disorders and liver dysfunction: Mechanisms of damage and therapeutic approaches.
World J Gastroenterol. 2025 Aug 28;31(32):108827. doi: 10.3748/wjg.v31.i32.108827.
3
Insulin resistance in school-age children: comparison surrogate diagnostic markers.
Pediatr Res. 2025 Aug 28. doi: 10.1038/s41390-025-04353-x.
6
Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation.
Med Sci (Basel). 2025 Aug 12;13(3):125. doi: 10.3390/medsci13030125.
8
Remnant cholesterol predicts the development of type 2 diabetes in patients with nonalcoholic fatty liver disease.
Diabetol Metab Syndr. 2025 Jul 18;17(1):277. doi: 10.1186/s13098-025-01828-z.
9
Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality.
Cardiovasc Diabetol. 2025 Jul 15;24(1):289. doi: 10.1186/s12933-025-02824-3.
10

本文引用的文献

1
Multiomics study of nonalcoholic fatty liver disease.
Nat Genet. 2022 Nov;54(11):1652-1663. doi: 10.1038/s41588-022-01199-5. Epub 2022 Oct 24.
2
Microbiome-derived ethanol in nonalcoholic fatty liver disease.
Nat Med. 2022 Oct;28(10):2100-2106. doi: 10.1038/s41591-022-02016-6. Epub 2022 Oct 10.
3
Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications.
Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:359-382. doi: 10.1146/annurev-pharmtox-032322-093904. Epub 2022 Sep 13.
5
Associations between Circulating SELENOP Level and Disorders of Glucose and Lipid Metabolism: A Meta-Analysis.
Antioxidants (Basel). 2022 Jun 27;11(7):1263. doi: 10.3390/antiox11071263.
7
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.
Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003. Epub 2022 Jun 3.
8
Sex hormone binding globulin as a potential drug candidate for liver-related metabolic disorders treatment.
Biomed Pharmacother. 2022 Sep;153:113261. doi: 10.1016/j.biopha.2022.113261. Epub 2022 Jun 20.
9
Fat Distribution Patterns and Future Type 2 Diabetes.
Diabetes. 2022 Sep 1;71(9):1937-1945. doi: 10.2337/db22-0315.
10
Deadenylase-dependent mRNA decay of GDF15 and FGF21 orchestrates food intake and energy expenditure.
Cell Metab. 2022 Apr 5;34(4):564-580.e8. doi: 10.1016/j.cmet.2022.03.005.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验